Can Treg therapy prevent GVHD?

Krishna V. Komanduri, Richard E. Champlin

Research output: Contribution to journalComment/debatepeer-review

11 Scopus citations


In this issue of Blood, Brunstein and colleagues report the results of the first study to test the safety of human umbilical cord blood - derived regulatory T cells (Tregs), an approach designed to decrease graft-versus-host disease.1 Transplanters, like Sisyphus of myth, have struggled mightily with trials of pharmacologic immunosuppressive drugs - we roll the rock up the mountain, only to see it roll back, leaving us where we began. This struggle has now led us to seek cellular therapies as a promising alternative.

Original languageEnglish (US)
Pages (from-to)751-752
Number of pages2
Issue number3
StatePublished - Jan 20 2011

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Can Treg therapy prevent GVHD?'. Together they form a unique fingerprint.

Cite this